+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ASTRAZEN

AstraZeneca Pharma India Share Price

₹7,946.50 -143.5 (-1.77%)

11 Aug, 2026 3:54 PM (IST)

AstraZeneca Pharma India live price: ₹7,946.50. It opened at ₹7,966 vs previous close ₹8,090; intraday high/low: ₹8,050/₹7,930. The 50 & 200 DMA stand at ₹8,232.60/₹8,437.50.

AstraZeneca Pharma India Performance

  • Today's Low
  • ₹7,930
  • Today's High
  • ₹8,050
  • 52 Week Low
  • ₹7,552
  • 52 Week High
  • ₹9,850
  • Open Price₹7,966
  • Previous Close₹8,090
  • Volume7,164
  • 50 DMA₹8,232.60
  • 100 DMA₹8,346.70
  • 200 DMA₹8,437.50

AstraZeneca Pharma India Chart

Investment Returns

  • Over 1 Month -2.11%
  • Over 3 Month -6.43%
  • Over 6 Month -11.32%
  • Over 1 Year -9.54%

Smart Investing Starts Here Start SIP with AstraZeneca Pharma India for Steady Growth!

Invest Now

AstraZeneca Pharma India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 117.1
  • PEG Ratio
  • -15.6
  • Market Cap Cr
  • 19,866
  • P/B Ratio
  • 22.8
  • Average True Range
  • 213.1
  • EPS
  • 67.8
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -29.2
  • RSI
  • 46.98
  • MFI
  • 17.2

Latest Stock News Updates

AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Please find the enclosed Press Release of the Company for your reference.

AstraZeneca Pharma India Ltd - 506820 - Shareholder Meeting / Postal Ballot-Outcome of AGM

Please find the enclosed intimation of the Company as per the captioned subject for your reference.

AstraZeneca Pharma India Q1 profit drops to 37.93 crore

Revenue from operations in Q1 stood at 682.79 crore as against 526.31 crore in the same period a year ago

AstraZeneca Pharma India Financials

AstraZeneca Pharma India Technicals

EMA & SMA

Current Price
₹7,946.50
-143.5 (-1.77%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹8,143.30
  • 50 Day
  • ₹8,232.60
  • 100 Day
  • ₹8,346.70
  • 200 Day
  • ₹8,437.50

Resistance and Support

7975.5 Pivot Speed
  • R3 8,862.30
  • R2 8,560.70
  • R1 8,325.30
  • S1 7,788.30
  • S2 7,486.70
  • S3 7,251.30

AstraZeneca Pharma India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-10 Quarterly Results
2026-05-26 Audited Results & Final Dividend
2026-02-11 Quarterly Results
2025-11-07 Quarterly Results
2025-08-14 Quarterly Results
Date Purpose Remarks
2026-07-31 FINAL Rs.36.00 per share(1800%)Final Dividend
2025-07-18 FINAL Rs.32.00 per share(1600%)Dividend
2024-07-05 FINAL Rs.24.00 per share(1200%)Dividend
2023-07-14 FINAL Rs.16.00 per share(800%)Dividend
2022-07-08 FINAL Rs.8.00 per share(400%)Final Dividend
View AstraZeneca Pharma India Dividend History Arrow
Date Purpose Remarks
2006-06-22 Split Stock split from Rs. 10/- to Rs. 2/-

AstraZeneca Pharma India Shareholding Pattern

75%
16.24%
6.01%
2.68%
0.07%

About AstraZeneca Pharma India

Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. View More
  • NSE Symbol
  • ASTRAZEN
  • BSE Symbol
  • 506820
  • ISIN
  • INE203A01020

Similar Stocks to AstraZeneca Pharma India

AstraZeneca Pharma India FAQs

AstraZeneca Pharma India share price is ₹7,946 As on 11 August, 2026 | 16:33

The Market Cap of AstraZeneca Pharma India is ₹19866.2 Cr As on 11 August, 2026 | 16:33

The P/E ratio of AstraZeneca Pharma India is 117.1 As on 11 August, 2026 | 16:33

The PB ratio of AstraZeneca Pharma India is 22.8 As on 11 August, 2026 | 16:33

The 52 week High & Low of AstraZeneca Pharma India is ₹9849.5/₹7551.5 respectively As on 11 August, 2026 | 16:33

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23